New Guidelines For Antiretrovirals

25 June 1997

A panel of experts has updated guidelines for HIV therapy, in responseto new data on the use of antiretrovirals in combination. The guidelines are published in the Journal of the American Medical Association (June 25).

The guidelines recommend that patients should begin antiretroviral therapy earlier in the course of the disease than before, with the stated goal of reducing viral load to below detectable levels. They note that the most effective treatment is a triple drug regimen, including two nucleoside analogs and one protease inhibitor, taken early in the infection and indefinitely thereafter.

The initial drugs chosen should be carefully selected after collaboration between patient and physician, and the physician should recommend a strategy that takes into account the patient's ability to comply with the strict regimens demanded by triple therapy. The importance of viral load monitoring in all caregiving settings was also emphasized.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight